Cihan Yurdaydin
University of Ankara · Ankara University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Cihan Yurdaydin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:18 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03069508 · Clemizole HCl for Subjects With Hepatocellular CarcinomaEiger Group International, Inc. · unknown · Hepatocellular Carcinoma · principal investigator
- Ph2NCT02430181 · Lonafarnib With and Without Ritonavir in HDV (LOWR-1)EIT Pharma, Inc. · completed · Chronic Hepatitis D Infection · principal investigator
- Ph2NCT02430194 · Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)EIT Pharma, Inc. · completed · Chronic Hepatitis D Infection · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:18 UTC. The ranking covers the 200 most relevant of 34 PubMed records, and a shared surname and initials can bring in a namesake. All 34 on PubMed
- Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med · 2004888 citationsRCR 21.4
- Peginterferon plus adefovir versus either drug alone for hepatitis delta.N Engl J Med · 2011376 citationsRCR 10.8
- Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.Gastroenterology · 2006312 citationsRCR 8.4
- Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.Ann Intern Med · 1995303 citationsRCR 8.8
- Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.Ann Intern Med · 1995290 citationsRCR 10.9
- Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.Gastroenterology · 2009258 citationsRCR 7.0
- 221 citationsRCR 6.0
- Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.Lancet Infect Dis · 2015210 citationsRCR 6.9
- Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.Lancet Infect Dis · 2019166 citationsRCR 6.6
- Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Hepatology · 2008135 citationsRCR 3.6